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Biomarkers that are identiﬁed from a single study often appear to be biologically irrelevant or false
positives. Meta-analysis techniques allow integrating data from multiple studies that are related but
independent in order to identify biomarkers across multiple conditions. However, existing biomarker
meta-analysis methods tend to be sensitive to the dataset being analyzed. Here, we propose a meta-
analysis method, iMeta, which integrates t-statistic and fold change ratio for improved robustness. For
evaluation of predictive performance of the biomarkers identiﬁed by iMeta, we compare our method
with other meta-analysis methods. As a result, iMeta outperforms the other methods in terms of
sensitivity and speciﬁcity, and especially shows robustness to study variance increase; it consistently
shows higher classiﬁcation accuracy on diverse datasets, while the performance of the others is highly
affected by the dataset being analyzed. Application of iMeta to 59 drug-induced liver injury studies
identiﬁed three key biomarker genes: Zwint, Abcc3, and Ppp1r3b. Experimental evaluation using RT-PCR
and qRT-PCR shows that their expressional changes in response to drug toxicity are concordant with the
result of our method. iMeta is available at http://imeta.kaist.ac.kr/index.html.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tremendous amount of data is piling up in public databases of
biological and medical ﬁelds. For instance, the Gene Expression
Omnibus database has more than 49,800 study records with over
1.2 million samples in 2014, and the overall submission rate con-
tinues to grow more and more rapidly [1]. Moreover, a number of
studies have been conducted in related topics repetitively and
independently. Accordingly, the potential for integrating these
invaluable resources has led researchers to advance biological and
medical insights that were formerly unrevealed from an individual
study [2e4]. In this regard, the development of effective data
integration technique should be essential.
Meta-analysis is a statistical technique for systematic inte-
gration of experimental outcomes from multiple studies that areInc. This is an open access article urelated but independent. Its main advantage is to boost power by
increasing sample size to be able to catch signals that are small
but consistent. In particular, one promising application is in the
ﬁeld of biomarker discovery (biomarker meta-analysis), whose
goal is to ﬁnd robust biomarkers (genes, proteins, or metabolites)
from inconsistent measurements among various studies, mainly
arising from biological and technical heterogeneities. For
instance, when identifying up- or down-regulated expressed
genes between two conditions, the amount of change can vary
from study to study, or sometimes even their signs (up or down)
can be inversed. In this situation, meta-analysis could efﬁciently
mitigate the issue by ﬁnding a consensus by means of summa-
rizing the outcomes.
Existing meta-analyses are classiﬁed into three categories ac-
cording to what to combine: p-value, t-statistic, and fold-change
ratio. First, Fisher's inverse chi-square method combines p-values
across k studies by summation of the logarithm of each p-value into
a single statistic, c22k 
Pk
i¼1lnðpiÞ, which is then compared
against chi-square distribution with 2k degree of freedom (Fisher)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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implement, and easily able to extend to more than two class
comparison. Unfortunately, however, it is unable to estimate the
magnitude of effect itself, so called effect size, which is often crucial
where we aim to estimate, for instance, how much the amount of
changes varies from study to study.
Second, t-statistic-based approach combines t-statistics from
multiple studies usually with weight regarding study variance.
A t-statistic itself captures a difference of two group means
standardized by its pooled standard deviation. The t-statistic-
based approach might be the most popular effect size-based
method, presumably due to its well-established statistical
background. However, practically, using t-statistic could be
easily dominated by outliers, thereby causing misleading esti-
mation. Moreover, inadequate variance estimation could make
the outcome (t-statistic) distorted. For instance, a comparison of
expression levels between two conditions could make a signal
(difference) underestimated due to large variance, often occur-
ring in complex diseases such as cancer whose samples usually
have a wide range of expression levels (i.e., large variance) [6].
As many researchers point out, t-statistic-based approach seems
preferred in a statistical sense rather than a biological sense
[7,8]. Several meta-analysis methods have been developed in
this category. Marot et al. and Wang et al. both use t-statistic but
differ in their effect size deﬁnition and implementation; a
moderated t-test statistic (Mod_t) [9] and a Bayesian framework
(Bayes_t) [10], respectively. Also, Choi et al. use t-statistic of
Hedge's and Olkin's [11], which corrects for biases due to small
sample size. It utilizes so called inverse-variance technique for
regarding within- and between-study variance, in which the
study weight is inversely proportional to the study variance
(GeneMeta) [12].
Third, fold-change-based approach is another effect size-based
method, which combines values utilizing fold-change ratio. A
fold-change ratio is simply a ratio between two representative
values, usually median, from each condition. An increase or
decrease of at least two fold, for instance, may be considered sig-
niﬁcant. Several features make this statistic useful for biomarker
discovery: its simplicity, biological intuitiveness, and resistance to
outliers. So, many studies using fold-change ratio ﬁnd that it often
offers more reproducible results than using t-statistic in microarray
analysis [7,8]. However, the major drawback comes from its ten-
dency to generate biased and erroneous outcomes mainly due to
the lack of variance consideration [13]. In this category, Hong et al.
propose a nonparametric rank product method utilizing the rank of
fold-change ratio, and shows that it is highly effective especially in
case of small sample sizes and large between-study variance
(RankProd).
In this study, we propose a method called iMeta, which com-
bines two types of effect size by integrating fold-change ratio and t-
statistic. Prior to the integration, fold-change ratios over multiple
studies are quantile-normalized against t-statistic distribution so as
to minimize bias arising from the distributional difference. This
approach aims at borrowing virtues of both effect size measure-
ments to achieve robustness. On top of that, study variance, serving
as weight for each study in combining multiple studies, is also
estimated under two assumptions: ﬁxed effect model (FEM) and
random effects model (REM).
To evaluate predictive performance r5of the biomarkers iden-
tiﬁed, we compare our method with other ﬁve existing methods
(Fisher, Mod_t, Bayes_t, GeneMeta, and RankProd), using three
simulation datasets and two actual datasets of drug-induced liver
injury (DILI). Computational and experimental evaluation shows
that biomarkers identiﬁed by iMeta are more robust over diverse
datasets in terms of sensitivity and speciﬁcity.2. Materials and methods
2.1. Deﬁnition of iMeta index
We review iMeta method here. The fundamental idea is to
integrate fold-change ratio and t-statistic over multiple studies
with weight regarding each study variance (Fig. S1). It comprises
three steps: 1) two independent statistical tests of gene i are per-
formed within a single study j; 2) the resulting t-statistic (T) and
fold-change ratio (F) are integrated in the control of parameter a,
whie the F distribution is normalized by quantile-normalization
function f against the T distribution so as to minimize bias arising
from distribution difference. [Eq. (2)]; and 3) a weighted mean over
k studies was calculated, whose weight uij is an inverse of study j's
variance, regarding within-study variance (s2ij) and between-study
variance (t2i ) [Eq. (6)]. The iMeta index, iM, is calculated as follows:
iMi ¼
Pk
j¼1uijEijPk
j¼1uij
(1)
Eij ¼ af

Fij
þ ð1 aÞTij (2)
Fij ¼ log2
bxtijbxcij (3)
Tij ¼
xtij  xcij
Sp
(4)
Sp ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðnc  1Þs2c þ ðnt  1Þs2t
nc þ nt  2
s
(5)
where Eij is an integrative effect size of gene i in study j, and a is a
parameter, called weight-on-fold-change, which determines rela-
tive weight of each statistic: higher values of a increase the impact
of fold-change ratio. Our method practically determines the value
of a from the dataset being analyzed, adjusting in a range between
0.0 and 1.0 by increment of 0.1 in a way to maximize an area under
receiver-operating-characteristic curve (AUC) value. bxt and bxc de-
notes the median value of expression levels in treatment (t) and
control (c) group, respectively, and xt and xc denotes the mean of
expression level of each group. Sp denotes an estimated pooled
standard deviation, where sc and st are standard deviation and nc
and nt are the number of samples in each group.
Many methods using t-statistic make two statistical model as-
sumptions on study variance: (i) Fixed effect model assumes that
true effect sizes are the same in all studies, but differences occur
from sampling error alone; (ii) Random-effects model assumes that
true effect sizes might be variable from study to study. Our method
implements both of the models. The weight uij, called weight-on-
study-variance, is deﬁned as an inverse of summation of within-
study variance s2ij and between-study variance t
2
i [Eq. (6)];
uij ¼
1
s2ij þ t2i
(6)
s2ij ¼
"
nc þ nt
ncnt
þ
E2ij
2ðnc þ ntÞ
#ð1aÞ
(7)
Fig. 1. Application to simulation datasets. (A) The behavioral properties of iMeta index with regard to weight-on-fold-change (a) are shown; higher values of a increase the impact
of fold-change ratio. The fraction of genes (left y-axis) that pass the fold-change threshold and the p-value threshold are represented in red and green, respectively. Right y-axis
represents the number of DEGs. (B) The ROC curves of iMeta with regard to various a. (C) The ROC curves of the six methods (Each AUC value in parenthesis). (D) The change of AUC
values according to the amount of between-study variance (Low, Medium, and High).
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B
t2 ¼ 0 if Fixed effect model (8)
 
Where
A ¼
Xk
j¼1
6ijE
2
ij 
Pk
j¼16ijEij
2
Pk
j¼16ij
(9)
6ij ¼ 1
.
s2ij (10)
B ¼
X
6ij 
P
62ijP
6ij
(11)
df ¼ k 1 (12)
The t2 is estimated by modiﬁcation of the method of moments,
called the DerSimonian and Laird method [Eqs. (9)e(12)] [14]. As
for ﬁxed effect model, t2 is set to zero.
2.2. Performance comparison with existing methods
Five meta-analysis methods were chosen according to the
popularity in each category. The versions of implementation werein the MAMA (Meta-Analysis of MicroArray) package in R:metaMA
with pvalcombination (Fisher) [5], metaMA with EScombination
(Mod_t), GeneMeta [12], RankProd [15], Bayes_t [16]. All was run as
default option except for GeneMeta and Bayes_t with 10,000 per-
mutations and for RankProd with 1000 permutations. For classiﬁ-
cation, Linear discriminant analysis (LDA) method was used, and
top ﬁve genes identiﬁed by each method were used as feature to
build a classiﬁcation model. Area under receiver-operating-
characteristic curve (AUC) value was used to evaluate perfor-
mance of classiﬁers with a leave-one-out cross validation (LOOCV).
2.3. Compiling analysis datasets
2.3.1. Simulation datasets
Three simulation datasets were compiled: S1, S2, and S3. S1 and
S2 consist of ten studies, while S3 comprises three datasets with
different levels of between study variance (Low, Medium, High),
each having ten studies (See Method S2.1.1 for detail). For the
context of meta-analysis, all the ten studies within a single dataset
need to be related to each other. To achieve this, a single matrix was
generated ﬁrst, and then fromwhich nine matrices were derived by
addition of levels of noises, comprising each study having 5%
differentially expressed genes (DEGs) and 95% non-differentially
expressed genes (NGs). Samples were simulated under two con-
ditions: control (C) and treatment (T).
Fig. 2. Application to actual datasets of drug liver toxicity. A and C show the ROC curves of iMeta according to three different weight-on-fold-change (a ¼ 0, 1, and 0.7) in DILI-I and
DILI-II, respectively. B and D show the ROC curves for the comparison among the six methods in DILI-I and DILI-II, respectively.
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Two groups of dataset of in vivo rat liver toxicity expression
proﬁles were collected and processed independently: DILI-I and
DILI-II. Expression proﬁles in DILI-I were downloaded from two
databases: Gene Expression Omnibus (GEO) [1], Chemical Effects in
Biological Systems (CEBS) [17]. Among all the 34 downloaded
studies, we ﬁnally selected 9 studies with the number of samples
3 in each class, having 596 samples in total (Table S1). All proﬁles
in DILI-II were downloaded from the Toxicogenomics Project-
Genomics Assisted Toxicity Evaluation system (TG-GATEs, http://
toxico.nibio.go.jp) [18]. Among all the 143 downloaded studies,
we ﬁnally selected 50 studies with the number of samples 3 in
each class, having 1494 samples in total (Table S2). Each samplewas
assigned a class (0: control, 1: toxicity shown) according to our
decision criteria (See Method S2.1.2 for detail). All datasets were
preprocessed: multiple probes per gene were averaged; expression
proﬁles were subjected to quantile normalization; genes with 50%
missing values and samples with more than 80% missing genes
were omitted.2.3.3. Experimental validation using RT-PCR and qRT-PCR
All experimental procedures are described Supplementary
Method S2.3, including the procedures of cell culture, cytotoxicity
test, mRNA isolation, semi-quantitative reverse transcription-PCR(RT-PCR), and real-time RT-PCR.
3. Results and discussion
3.1. Predictive performance evaluation
We used diverse datasets to evaluate predictive performance of
each classiﬁer using features (genes) identiﬁed by each method.
The datasets include three simulation datasets (S1, S2 and S3) and
two real liver injury datasets (DILI-I and DILI-II). The resulting
meta-analyses for simulation and actual datasets are available on
our website http://imeta.kaist.ac.kr/index.html.
For each dataset, we ﬁrst identiﬁed ﬁve the most differentially
expressed genes by using each method (iMeta, Fisher, Mod_t,
Bayes_t, GeneMeta, and RankProd) in order to choose a small
number of relevant biomarkers. These ﬁve key genes were used as
features to build a classiﬁer to discriminate a treatment group from
a control group. Then, we evaluated their predictive performance in
terms of AUC value, representing both sensitivity and speciﬁcity.
AUC of 0.5 and 1 represent a random guess and a perfect prediction,
respectively.
3.1.1. Application to simulation datasets
We applied all the methods to three simulation datasets. For
Table 1
Functional and disease information using top highly ranked genes.
No Gene *p-
value
[/Y Function Known related diseases
1 Dhtkd1 2.16E-
08
Y Involved in the degradation pathways of several amino acids, including lysine Reye syndrome
2 Ppp1r3c 3.07E-
08
Y Catalyzes reversible protein phosphorylation, which is important in a wide range of cellular activities:
neuronal, muscular, RNA splicing, protein synthesis, cell death, and glycogen metabolism
Lafora disease
3 Lcn2 7.24E-
08
[ GO annotations related to this gene include iron ion binding and protein homodimerization activity Nephrotoxicity
Osmotic Stress
4 Zwint 3.56E-
07
[ Involved in kinetochore function although an exact role is not known Roberts syndrome
5 Abcc3 7.92E-
07
[ Involved in multi-drug resistance. The speciﬁc function of this protein has not yet been determined;
however, this proteinmay play a role in the transport of biliary and intestinal excretion of organic anions
Drug Transporters Cancer Drug
ResistanceHepatotoxicity
6 Otc 8.21E-
07
Y Encodes a mitochondrial matrix enzyme. Missense, nonsense, and frameshift mutations in this enzyme
lead to ornithine transcarbamylase deﬁciency, which causes hyperammonemia
Amino Acid Metabolism I
7 Hmox1 9.03E-
07
[ An essential enzyme in heme catabolism, cleaves heme to form biliverdin, which is subsequently
converted to bilirubin by biliverdin reductase, and carbon monoxide, a putative neurotransmitter
Oxidative Stress
Hepatotoxicity
8 Kmo 3.72E-
06
Y Encodes a mitochondrion outer membrane protein that catalyzes the hydroxylation of L-tryptophan
metabolite, L-kynurenine, to form L-3-hydroxykynurenine
Amino Acid Metabolism I
9 Thrsp 4.08E-
06
Y Similar to the gene product of S14, a rat gene whose expression is limited to liver and adipose tissue and
found to be expressed in lipogenic breast cancers, which suggests a role in controlling tumor lipid
metabolism
Hepatotoxicity
10 Cﬂ1 6.73E-
06
[ Involved in the translocation of actin-coﬁlin complex from cytoplasm to nucleus Cytoskeleton Regulators
Apoptosis 384HT
11 Ccng1 8.35E-
06
[ The eukaryotic cell cycle is governed by cyclin-dependent protein kinases (CDKs) whose activities are
regulated by cyclins and CDK inhibitors
Nephrotoxicity
Hepatotoxicity
12 Rexo2 8.69E-
06
[ May have a role in DNA repair, replication, and recombination, and in RNA processing and degradation Leukemia
13 Cgref1 1.07E-
05
[ GO annotations related to this gene include calcium ion binding Dermatitis
14 Aadac 1.16E-
05
Y Catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine
carcinogens
Drug Metabolism
15 Sez6 1.22E-
05
Y Diseases associated with SEZ6 include febrile seizures, and cerebritis Febrile seizures
16 Rarres1 1.24E-
05
Y Identiﬁed as a retinoid acid (RA) receptor-responsive gene Schizophrenia
17 Ppp1r3b 1.24E-
05
Y Expressed in liver and skeletal muscle tissue and may be involved in regulating glycogen synthesis in
these tissues
Hepatitis
Alzheimer's disease
18 RGD1309534 1.40E-
05
Y Function unknown e
19 Ddc 1.42E-
05
Y Defects in this gene are the cause of aromatic L-amino-acid decarboxylase deﬁciency (AADCD). AADCD
deﬁciency is an inborn error in neurotransmitter metabolism that leads to combined serotonin and
catecholamine deﬁciency
Amino Acid Metabolism I
Amino Acid Metabolism II
20 Cidea 1.77E-
05
[ Mice that lack functional Cidea have higher metabolic rates, higher lipolysis in brown adipose tissue and
higher core body temperatures when subjected to cold
Apoptosis
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regard to a using S1 (Fig. 1A). The parameter a is a weight factor
that determines relative weight between fold-change ratio and t-
statistic. iMeta is run with various a s, ranging from 0.0 to 1.0 by
increment of 0.1. For each a, we identiﬁed signiﬁcantly differen-
tially expressed genes (meta-p<1.0e-12), and then among which
we counted both the number of genes that pass through (i) a fold-
change ratio threshold (red, jFCj>3) and (ii) a p-value threshold
(green, t-test p < 1.0e-12). The result indicates that higher value of a
includes more genes with higher fold-change ratio, whereas lower
value of a includes more genes with signiﬁcant t-test p-value;
meanwhile, the number of DEGs identiﬁed was shown nearly
invariant.
Next, we compared predictive performance of each method
using simulation dataset S2. At the beginning, for iMeta, the best a,
producing the highest AUC, was examined ﬁrst and ﬁnally set to
a ¼ 0.4 (AUC ¼ 0.986) (Fig. 1B). In addition, the a that produces the
lowest AUC was 0.0 (AUC ¼ 0.935), which means using only t-sta-
tistic. The AUC of using only fold-change ratio (a¼ 1.0, AUC¼ 0.951)
was slightly higher than that of using only t-statistic. With a being
set to 0.4, its predictive performance was further compared to the
other ﬁve methods (Fig. 1C). As a result, the classiﬁer using features
identiﬁed by iMeta was shown to have slightly better performance
(AUC ¼ 0.99) than the other methods, which is followed by Mod_t(AUC ¼ 0.95), Fisher (AUC ¼ 0.95), GeneMeta (AUC ¼ 0.94), Bayes_t
(AUC ¼ 0.78) and RankProd (AUC ¼ 0.71).
Furthermore, we examined as to how between-study variance
affects to the predictive performance of each method. To achieve
this, we used dataset S3, each having a different level of between-
study variance (Low, Medium and High). As shown in Fig. 1D, as the
amount of between-study variance increases, the predictive per-
formance appears to decrease. Speciﬁcally, as between-study
variance increases, the AUCs of Fisher, Mod_t, GeneMeta, and
Bayes_t are likely to decrease substantially, whereas those of iMeta
appear to be highly tolerant to the variance increase. As for Rank-
Prod, although its AUCs are shown to increase, it might be possibly
due to its unstable performance, judging from its low AUC values.
This result indicates that applying iMeta to actual datasets could be
robust to the sheer amount of noises arising from various technical
and biological heterogeneities.
3.1.2. Application to actual datasets
Next, we applied all the methods to actual datasets of drug-
induced liver injury (DILI). Liver injury is a leading cause of acute
liver failure as well as one of the most common reasons for post-
marketing withdrawals of many drugs [19,20].
For DILI biomarker discovery, we used two groups of actual
dataset, which were independently collected and processed. They
Fig. 3. Experimental validation of three biomarkers: Zwint, Abcc3, and Ppp1r3b. A-C and D-F represent forest plots of the three genes in DILI-I and DILI-II, respectively. The y-axis
represents the number studies analyzed, and x-axis represents both Log2FC and t-statistic at the same time. A blue circle with bar represents a t-statistic with 95% conﬁdence
interval, and a black star represents log-2-fold-change-ratio. GeI shows the results of real-time quantitative PCR of the three genes, showing expressional changes after a toxic
intervention of an overdose of APAP to HepG2 cells. The x- and y-axis represent the concentration of APAP and the fold-change ratio, respectively. J-L shows the images of
expressional changes by reverse transcription PCR; GAPDH was used as a control.
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toxicity: DILI-I and DILI-II were used as a training and a test dataset,
respectively. For eachmethod, the evaluationwas carried out as the
same in the simulation dataset analysis. That is, we evaluated how
well the classiﬁer built with features identiﬁed in DILI-I analysis
discriminates the liver toxicity samples from control samples in
using DILI-II dataset, whose classes are already known.
First, for DILI-I dataset, as for iMeta, the parameter a was
adjusted ﬁrst and ﬁnally set to 0.7 (Fig. 2A). For simplicity, out of all
the eleven (0.0a 1.0 by increment of 0.1) receiver-operating-
characteristic (ROC) curves, only three are shown: eachrepresenting using (i) fold-change ratio only (grey, a ¼ 1.0,
AUC¼ 0.85); (ii) t-statistic only (black, a¼ 0.0, AUC¼ 0.77); and (iii)
integrating fold-change ratio and t-statistic (red, a ¼ 0.7,
AUC ¼ 0.86). Then, we compared predictive performance among
the other methods (Fig. 2B). The result shows that iMeta out-
performs the other methods (AUC ¼ 0.86), which is followed by
Fisher (AUC ¼ 0.81), Mod_t (AUC ¼ 0.76), RankProd (AUC ¼ 0.76),
Bayes_t (AUC ¼ 0.72), and GeneMeta (AUC ¼ 0.65).
Next, for DILI-II dataset, the same conditions were applied as in
the DILI-I analysis: the a was set to 0.7 for iMeta, and the same
features, having been identiﬁed by each method in DILI-I analysis,
H. Cho et al. / Biochemical and Biophysical Research Communications 471 (2016) 274e281280were used. In Fig. 2C, three ROC curves for each a for iMeta using
DILI-II were shown: a ¼ 0.0 (black, AUC ¼ 0.85), ¼ 1.0 (grey,
AUC ¼ 0.75), and a ¼ 0.7 (red, AUC ¼ 0.88), indicating that inte-
grating both fold-change ratio and t-statistic could improve pre-
dictive performance. Further, we compared the performance
among the other methods, and the result shows that iMeta also
outperforms the others (AUC ¼ 0.88), which is followed by Mod_t
(AUC ¼ 0.84), Fisher (AUC ¼ 0.80), RankProd (AUC ¼ 0.75), Bayes_t
(AUC ¼ 0.72), and GeneMeta (AUC ¼ 0.71) (Fig. 2D).
Notably, Fisher andMod_t are the second best method following
iMeta in DILI-I and DILI-II, respectively. Although the performance
gain by iMeta appears to be modest in terms of the increase of AUC
(from 0.81 to 0.86 and from 0.84 to 0.88 in DILI-I and DILI-II,
respectively), the result underlines that AUCs of iMeta are consis-
tently higher than those of the othermethods over diverse datasets,
regardless of simulation- and actual datasets. We suppose that the
strength might come from its ability to capture beneﬁts from both
statistics.
3.2. Biological implication to drug induced liver toxicity
Table 1 summarizes genes that are highly ranked by iMeta in
drug induced liver toxicity, indicating most genes are related to the
liver function. For instance, Dhtkd1 is involved in the degradation
pathways of several amino acids such as lysine, and is also known to
be related to Reye syndrome, which shows numerous detrimental
effects especially to the brain and liver causing a lower blood sugar
level (hypoglycemia) [21].
Furthermore, we carried out the functional analysis of Gene
Ontology (GO) enrichment test and protein interaction network
analysis using top thirty genes (Fig. S3; See Method S2.2 for detail.).
First, we examined how well those genes are functionally enriched
by GO enrichment test, resulting in that the signiﬁcant GO terms
are relevant to several liver function (Fig. S3A). Speciﬁcally, the
result shows that the biological processes that were over-
represented are many drug-related processes: ‘response to chem-
ical stimulus’ (GO:0042221; p ¼ 5.50E-06), ‘regulation of transport’
(GO:0051049; p ¼ 2.22E-03), and ‘exocytosis’ (GO:0016195;
p ¼ 4.28E-03). Also, several apoptosis-related processes were
overrepresented such as ‘apoptosis’ (GO:0042221; p ¼ 9.33E-05)
and ‘caspase activation’ (GO:0006919; p ¼ 1.31E-03). Next, their
protein interaction network was derived utilizing public databases
of proteineprotein and protein-DNA interaction, which improve
our understanding of protein function and cellular processes
related to the liver function (Fig. S3B). The corresponding GO terms
are coded in the same color.
3.3. Experimental validation of the genes by iMeta with qRT-PCR
and RT-PCR
We performed an experimental validation of the outcome of our
method. At the beginning, we induced drug toxicity to HepG2 hu-
man liver cell line by overdosing acetaminophen (APAP), which is
known to derive liver toxicity (Fig. S4). Then, we examined its
expressional changes before (control) and after (treatment) toxic
treatment by using real-time quantitative PCR (qRT-PCR) and
reverse transcription-PCR (RT-PCR).
To this end, ﬁrst we prioritized genes for validation. Forest plots
provide a way to illustrate effect sizes of every study, fold-change
ratio and t-statistic, at a glance. As shown in Fig. S2A, top ﬁve
genes were highlighted in DILI-I: Dhtkd1 (meta-p ¼ 2.16e-08),
Ppp1r3C (meta-p ¼ 3.07e-08), Lcn2 (meta-p ¼ 7.24e-08), Zwint
(meta-p ¼ 3.56e-07) and Abcc3 (meta-p ¼ 7.92e-07). And then, we
examined all their functional subunits being also highly ranked,
which results in the addition of Ppp1r3b (meta-p ¼ 1.24e-05) into acandidate list. Among the six genes, we ﬁnally selected three genes
highly signiﬁcant in DILI-II: Zwint (meta-p¼ 1.5e-44), Abcc3 (meta-
p ¼ 1.2e-38), and Ppp1r3b (meta-p ¼ 2.1e-16) (Fig. 3AeC for DILI-I,
3D-F for DILI-II).
As a result, their expressional changes were found to be
concordant with the outcome our method (Fig. 3GeI). Their
expressional level is signiﬁcantly changed: Zwint (n ¼ 5, t-test
p ¼ 3.96e-02) and Abcc3 (n ¼ 5, t-test p ¼ 4.116e-06) were signif-
icantly over-expressed, and Ppp1r3b (n ¼ 5, t-test p ¼ 2.34e-02)
signiﬁcantly under-expressed. The fold-change ratios as well as 95%
conﬁdence interval of Zwint, Abcc3, and Ppp1r3b are 3.07 ± 1.04,
4.02 ± 0.59, and 0.45 ± 0.24, respectively. The corresponding RT-
PCR image, representing the amount of gene expressions, of each
gene was also shown to be reproducible (Fig. 3JeL). This result
demonstrates that integrating two effect sizes could improve the
robustness of biomarkers from multiple studies and thus facilitate
the advance of biomarker discovery.
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